**27 July 2026**

ASX Announcement

# Techknow Invest Roadshow presentation

**MELBOURNE Australia, 27 July 2026:** Australian antiviral drug development company, Island Pharmaceuticals Ltd (**ASX: ILA**; **Island** or **the Company**) advises that non-executive chairman, Mr Jason Carroll will present at the TechKnow Invest Roadshow in Melbourne on 27 July 2026 and in Sydney on 29 July 2026.

The presentation will provide investors with an overview of the Company, including recent progress across its regulatory and clinical development programs, the advancement of Galidesivir under the FDA's Animal Rule pathway for Marburg Virus Disease, and the continued expansion of Island's antiviral pipeline.

The presentation will also highlight recent milestones, including the Company's progress associated with FDA-directed dose optimisation studies, Ebola preparedness initiatives under the World Health Organization's MEURI framework, and the broader commercial opportunity for Galidesivir across biodefence and emerging infectious disease markets.

A copy of the presentation is attached to this announcement.

**- Ends -**

**Approved for release to the ASX by the Board.**

David Foster (CEO and Managing Director)
Island Pharmaceuticals Limited
info@islandpharmaceuticals.com

Investors and media, for further information, please contact:

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

**About Island Pharmaceuticals**

Island (ASX: ILA) is focused on areas of unmet need for drugs that can address urgent viral diseases, public health or biosecurity threats. The Company is executing a dual development strategy for its assets, ISLA-101 and Galidesivir.

ISLA-101 has a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika and Yellow fever – viruses with significant unmet medical needs and that may contribute to national security threats.

*Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.*

Visit www.islandpharmaceuticals.com for more on Island.

ISLAND PHARMACEUTICALS

# COMBATTING URGENT VIRAL DISEASE THREATS

## TechKnow 2026 Investor Roadshow

Mr. Jason Carroll - Non-Executive Chairman – Dr. David Foster – CEO & Managing Director

**July 2026**

**ASX: ILA**

# DISCLAIMER

**Important Information**
This disclaimer applies to this presentation and the information contained in it (**Presentation**). By reading this disclaimer you agree to be bound by it. The Presentation has been prepared by Island Pharmaceuticals Limited and all related bodies corporate (**Company**).

**Confidential information**
The Presentation is confidential and is intended only for the person to whom it was first given. By receiving the Presentation, you agree to keep it confidential, not to disclose it to any other person and not to copy, use, publish, record or reproduce it, in whole or in part, without the prior written consent of the Company, which may be withheld in its absolute discretion.

**Not an offer or financial product advice**
The Presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in the Company nor does it constitute financial product advice. The Presentation is not a prospectus, product disclosure statement, pathfinder for the purposes of section 734(9) of the *Corporations Act 2001* (Cth) or other offer document under Australian or New Zealand law or under any other law. The Presentation has not been filed, registered or approved by regulatory authorities in any jurisdiction.
The Presentation is not intended to be relied upon as advice or a recommendation to investors and does not take into account the investment objectives, financial situation, taxation situation or needs of any particular investor. An investor must not act on the basis of any matter contained in the Presentation but must make its own assessment of the Company and conduct its own investigations and analysis. Investors should assess their own individual financial circumstances and consider talking to a financial adviser, professional adviser or consultant before making any investment decision.

**Information purposes only**
The Presentation is for information purposes only. It provides an overview of the Company but may not contain all information necessary to make an investment decision. The Presentation is of a general nature and does not purport to be complete or verified by the Company or any other person. The Company does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of the Presentation, which may affect any matter referred to in the Presentation. The information in the Presentation is subject to change without notice.

**No guarantee, representation or warranty**
While reasonable care has been taken in relation to the preparation of the Presentation, none of the Company or their respective directors, officers, employees, contractors, agents, or advisers nor any other person (**Limited Party**) guarantees or makes any representations or warranties, express or implied, as to or takes responsibility for, the accuracy, reliability, completeness or fairness of the information, opinions, forecasts, reports, estimates and conclusions contained in the Presentation. No Limited Party represents or warrants that the Presentation is complete or that it contains all information about the Company that a prospective investor or purchaser may require.
To the maximum extent permitted by law, each Limited Party expressly disclaims any and all liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of or reliance on information contained in the Presentation including representations or warranties or in relation to the accuracy or completeness of the information, statements, opinions, forecasts, reports or other matters, express or implied, contained in, arising out or derived from, or for omissions from the Presentation including, without limitation, any financial information, any estimates or projections and any other financial information derived therefrom.

**Forward-looking statements**
The Presentation includes forward-looking statements and comments about future events, including the Company's expectations about the performance of its businesses. Forward-looking words such as "expect", "should", "could", "may", "predict", "plan", "will", "believe", "forecast", "estimate", "target" or other similar expressions are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company and which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. Forward-looking statements are provided as a general guide only, and should not be relied on as an indication or guarantee of future performance. Given these uncertainties, recipients are cautioned to not place undue reliance on any forward-looking statement. Subject to any continuing obligations under applicable law, the Company disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements in the Presentation to reflect any change in expectations in relation to any forward-looking statements or any change in events, conditions or circumstances on which any such statement is based.
No Limited Party or any other person makes any representation, or gives any assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in the Presentation will occur.

**Past performance**
Past performance is not indicative of future performance and no guarantee of future returns is implied or given.

**Representations, warranties and acknowledgement**
This document is provided to you in consideration of you making the statements set out below. By accepting this document, you:
- represent and warrant that you are a person to whom an offer of securities can be made without a disclosure document:
- in Australia, because of subsections 708(8), (10) or (11) of the Corporations Act; or
- in New Zealand, because you (i) are an investment business within the meaning of clause 37 of Schedule 1 of the Financial Markets Conduct Act 2013 (the FMC Act), (ii) meet the investment activity criteria specified in clause 38 of Schedule 1 of the FMC Act, (iii) are large within the meaning of clause 39 of Schedule 1 of the FMC Act, (iv) are a government agency within the meaning of clause 40 of Schedule 1 of the FMC Act or (v) are an eligible investor within the meaning of clause 41 of Schedule 1 of the FMC Act;
- You are either (a) not a "U.S. person" as that term is defined in Regulation S under the Securities Act, are not in the United States, and are not acting for the account or benefit of a U.S. person, or (b) a "qualified institutional buyer" as that term is defined in Rule 144A under the Securities Act;
- represent and warrant that you will act on the basis of your own investigations and analysis and place no reliance on this Presentation;
- acknowledge that this Presentation does not purport to contain all of the information that you may require for the purpose of making an investment in the Company, is not a prospectus and does not contain the same degree or standard of information as a prospectus, and has not been checked, verified or assessed for accuracy or completeness by external advisers, intermediaries or independent experts, nor by any party who has distributed those documents on behalf of the Company.
- no representation or warranty (express or implied) is made by the Company as to the accuracy, completeness, likelihood of achievement or reasonableness of any projections and forward looking statements in this presentation, nor of the assumptions on which the projections and forward looking statements are based, and projections and forward looking statements are not guarantees of future performance but are by their nature subject to significant uncertainties and contingencies. There can be no assurance or guarantee that such projections and forward looking statements will be realised; and
- acknowledge that the Company, and its related bodies corporate rely on you complying with this disclaimer and on the truth and accuracy of the representations and warranties given by you.

# ISLAND PHARMACEUTICALS (ASX: ILA)

## TWO PROGRAMS TARGETING INFECTIOUS DISEASES

- Two, well advanced clinical stage programs
- Major market potential via both programs
- Both assets have Priority Review Voucher potential
- Phase 2a/b PROTECT clinical trial in dengue complete
- Positive FDA feedback on Animal Rule regulatory path
- Multiple near term clinical trial, operational and regulatory catalysts

# Company Overview

| | |
|---|---|
| **Shares on issue[1]:** | **295,916,682** |
| **Price per share[1]:** | **$0.40** |
| **Market capitalisation[1]:** | **$118.6m** |
| **Cash at bank (31 March 2026)[2]:** | **$14.2m** |
| **Potential additional capital from vested options where current share price exceeds exercise price:** | **~$1.6m** |
| **Debt:** | **Nil** |

**Price & volume (12 months)**




| **Substantial shareholders** | |
|---|---|
| Dr William James Garner[3] | 15.50% |
| Jason Alan Carroll[3] | 11.92% |
| MWP Partners Limited[4] | 8.25% |
| Dr Daniel Tillett[3] | 7.80% |

| **Board of Directors** |
|---|
| Jason Carroll, Non-Executive Chairman |
| Dr David Foster, CEO & Managing Director |
| Chris Ntoumenopoulos , Non-Executive Director |

1. As at 24 July 2026
2. Does not take into consideration cash movement since reporting date
3 Per holding per Substantial interest notice lodged with ASX on 9 December 2025
4 Per holding per Substantial interest notice lodged with ASX on 3 June 2025

# Ebola & Marburg Viral Threats

## An urgent and growing global security challenge

**Extremely high fatality rates: Marburg up to 88%, Ebola up to 90%, Sudan up to 47%, Bundibugyo 30–50%**

**Limited countermeasures:** No approved therapeutics or vaccines for Marburg or Bundibugyo

**BSL-4 pathogens:** Require maximum containment; limited global capacity

**Bioterror relevance:** Historical weaponisation research; persistent intelligence concern

**Current situation:** Ongoing Bundibugyo outbreak with no available medical countermeasures

### THE WORLD LACKS A BROAD-ACTING ANTIVIRAL CAPABLE OF ADDRESSING MULTIPLE FILOVIRUS THREATS

**There are no flovirus therapeutics capable of cross-strain protection**

**Galidesivir directly addresses this gap**

- Existing Ebola countermeasures are strain-specific (Zaire only)
- No approved therapeutics for Marburg, Bundibugyo or Sudan virus
- Outbreaks increasingly involve rare or divergent strains
- Stockpile lacks a broad-acting antiviral with Animal Rule feasibility

# Galidesivir is designed as a Biodefence countermeasure to protect and defend the backbone of US National Security

ILA's stockpile strategy ensures full treatment coverage for the 10,000+ individuals critical to outbreak containment and continuity of government – from POTUS + Cabinet to Essential Infrastructure Leaders & their families

| Tier | Estimated Headcount | Notes |
|---|---|---|
| President + Cabinet | ~25 | Includes POTUS, VP, Cabinet Secretaries |
| Congressional Leadership | ~50 | Speaker, Majority/Minority Leaders, Committee Chairs |
| Supreme Court | 9 | All Justices |
| National Security & Defense Heads | ~100 | Joint Chiefs, DHS, CIA, NSA, FEMA, etc. |
| Continuity-of-Government Staff | ~500–1,000 | Includes designated survivors, relocation site personnel |
| HHS/CDC/FDA Leadership | ~200 | Key public health and regulatory officials |
| State Governors + Key Staff | ~1000 | 50 governors + emergency response leads |
| Tier 1 Healthcare Response Teams | ~5,000–10,000 | BSL-4 lab staff, frontline responders, quarantine facility personnel |
| Essential Infrastructure Leaders | ~2,000–5,000 | Power grid, water, telecom, transport continuity |






Note : Minimum assumption for mandatory holding of Galidesivir doses includes **17,500 for High Priority populations** plus at least dosing for **1 family member = 35,000 doses**

# Dual Development Strategy

**Two complementary pathways advancing Galidesivir towards regulatory approval**

| **Pathway 1** | **Pathway 2** |
|---|---|
| **FDA Animal Rule Program** | **Human Ebola Study** |
| USAMRIID Marburg challenge study | WHO MEURI Framework |
| Controlled non-human primate efficacy data | Real-world clinical data |
| Marburg virus model | Bundibugyo Ebola infected patients |
| Controlled efficacy supporting FDA Animal Rule | Human efficacy, safety and virological data |

**Together, these complementary pathways combine prospective human clinical data with controlled non-human primate efficacy studies, strengthening Galidesivir's regulatory package and development pathway.**

# Animal Rule disrupts the established Regulatory Path





**Confirmed PRV opportunity with a potential value of ~US$200m**

Island is now focused on advancing Galidesivir's clinical development pathway, which includes a dose optimisation study to commence shortly with USAMRIID

# Government-Approved Africa Protocol

## Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) framework

**Government approvals have been secured to evaluate Galidesivir during the active Bundibugyo Ebola outbreak in Uganda under the WHO MEURI framework, creating a unique opportunity to generate prospective human clinical data.**

### Overview

- Government and regulatory approvals secured for compassionate use of Galidesivir.
- Patient treatment expected to commence in CY26.
- Clinical, safety and virological data will be prospectively collected throughout treatment.

### WHO MEURI Framework

- A World Health Organization emergency framework for evaluating investigational medicines during disease outbreaks where no approved treatment exists.
- Enables patients to access promising therapies while generating valuable clinical evidence.

### Strategic Importance

- First opportunity to evaluate Galidesivir during an active Ebola outbreak.
- Generates prospective human data in the intended disease setting.
- Complements the FDA Animal Rule program, strengthening Galidesivir's overall development strategy.

**PARTNERS**

Uganda Ministry of Health
ACCEPT-Africa Infectious Diseases Institute
World Health Organization

# Regulatory & Commercial Opportunity

## A clear pathway to regulatory approval and commercialisation

### Regulatory pathway for Galidesivir

- FDA Animal Rule supported by pivotal Marburg efficacy studies.
- WHO MEURI framework providing prospective human data in Ebola or other outbreaks.

### Priority Review Voucher (PRV)

- PRV eligibility upon FDA approval.
- A PRV may be used to accelerate FDA review of another product or sold in the secondary market.

### Government Procurement

- Potential procurement by U.S. and international governments following regulatory approval.
- Commercial opportunity supported by global biodefence and pandemic preparedness initiatives.

### Strategic National Stockpile

- Potential inclusion in government biodefence stockpiles for high-consequence viral threats.

# MARBURG NHP SURVIVAL

**94% survival in Marburg NHP Model with treatment initiated up to 48 hours post-infection**




- 6/6 animals survived when dosed 48 hours post infection
- 6/6 animals survived when dosed 24 hours post infection
- 5/6 animals survived when dosed 1 hour post infection

**0/6 untreated animals survived as part of the control group**

nature

**This level of efficacy, with a clinically meaningful therapeutic window, is rare in filovirus models and directly supports Animal Rule advancement**

# EBOLA NHP SURVIVAL

## Robust efficacy in Ebola NHP model with delayed dosing

Survival of rhesus non-human primates challenged with Ebola virus following intramuscular administration of 100 mg/kg BID loading dose followed by 25 mg/kg BID for 10 days.




- **100% survival when treatment commenced 2 days post infection**
- **67% survival when treatment commenced 3 days post infection**
- **67% survival when treatment commenced 2 days post Infection with no loading dose**

**0% survival in untreated controls**

Warren, T. K. et al. Efficacy of Galidesivir Against Ebola Virus Disease in Rhesus Monkeys. Poster Presentation ID Week 2017

**Together with Marburg data, this positions Galidesivir as a multi-filovirus antiviral candidate**

# A PROVEN PATH FOR BIOTERROR THREAT COUNTERMEASURES

| Company | Product | Year Approved | Disease Treated | SNS Sales (USD) | Contract Term | Under SNS Contract |
|---|---|---|---|---|---|---|
| Emergent BioSolutions | raxibacumab | 2012 | Inhalational Anthrax | ~$450M | ~5 yrs | Yes |
| Kaléo | AUVI-Q | 2012 | Anaphylaxis (emergency countermeasure) | ~$100M+ | Expired | No (contract expired) |
| Emergent BioSolutions | BioThrax / CYFENDUS | 2015 | Anthrax (prophylactic vaccine) | ~$1.3B+ | ~5 yrs | Yes |
| Elusys Therapeutics | Anthim | 2016 | Inhalational Anthrax | ~$500M+ | ~5 yrs | Yes |
| SIGA Technologies | TPOXX | 2018 | Smallpox | ~$1.0B+ | 10 yrs | Yes |
| Paratek Pharmaceuticals | Nuzyra | 2018 | Anthrax (post-exposure prophylaxis) | ~$150M+ | ~5 yrs | Yes |
| Bavarian Nordic | Jynneos | 2019 | Smallpox / Mpox | ~$600M+ | ~10 yrs | Yes |
| Regeneron | Inmazeb[1] | 2020 | Ebola (Zaire ebolavirus) | ~$345M | 6 yrs | Yes |
| Ridgeback / Emergent | Ebanga[1] | 2020 | Ebola (Zaire ebolavirus) | ~$700M+[2] | 10 yrs | Yes |
| Chimerix / Emergent | Tembexa | 2021 | Smallpox | ~$400M+ | 10 yrs | Yes |

Since 2012, the FDA's Animal Rule approval has led to 8 bioterror countermeasures joining the US Strategic National Stockpile (SNS)

In 7 out of 8 cases, these medical countermeasures continue to remain under SNS contract and have generated 'lifetime sales' of between US$150m – US$1.3Bn at an average of ~US$625m

~US$600m has been provided through grants to develop a Marburg countermeasure with no tangible results

Marburg is the only Category A biothreat that has no treatment presently available in the Strategic National Stockpile

FDA approval of Galidesivir in Marburg provides a significant opportunity for a Priority Review Voucher as well as a multi-year SNS contract

[1] Inmazeb and Ebanga were approved on efficacy against Zaire ebolavirus demonstrated during an Ebola outbreak (PALM trial, DR Congo), not under the FDA Animal Rule.
[2] Ebanga figure reflects the BARDA contract ceiling (up to ~US$704M over 10 years), not realised sales to date.

# Near-Term Catalysts

## A number of value catalysts pending in the coming months

| Milestone | Timeframe |
|---|---|
| Establish Fellows Program to provide expert access to strategic subject matter KOLs | Complete |
| FDA feedback on Galidesivir protocol clarifying questions | Received |
| Government-approved deployment of Galidesivir under the WHO MEURI framework in Uganda | Received |
| Prospective human clinical, safety and virological data generation from MEURI framework | Q4 CY26- Q2 CY27 |
| Commencement of Galidesivir's development plan in non-human primates (NHP) | Initiated |
| Galidesivir NHP minimum effective dose study and PK study (20 NHPs) | Q4 CY26 |
| Galidesivir NHP Time of dose post-infection study program (12 NHPs) | Q1 CY27 |
| Galidesivir NHP pivotal Marburg study (~24 NHPs) | Q2 CY27 |
| NDA preparation (Marburg / Ebola) | Q3 CY27 |
| Explore partnership and international government engagement opportunities | Ongoing |

Dates are indicative only, based on current estimates and subject to change

ISLAND
PHARMACEUTICALS

# Island Pharmaceuticals

## ASX: ILA


dfoster@islandpharmaceuticals.com

islandpharmaceuticals.com

@IslandPharma

Island Pharmaceuticals